Abstract
Purpose
To investigate the precise function of Cullin1 (CUL1) in colorectal cancer (CRC).
Methods
Immunohistochemistry was performed to test the expression of CUL1 on a CRC tissue microarray containing the tumor and corresponding normal tissues. Simultaneously, the correlation of CUL1 expression with clinicopathological parameters and survival was evaluated. CUL1 was over-expressed or knocked down in HCT116 and SW480 cells, then the cell proliferation, migration and invasion assays in vitro and in vivo were performed.
Results
In this study, we found that CUL1 expression was significantly up-regulated in CRC compared with normal colon tissues. High CUL1 expression was positively associated with lymph node metastasis (P = 0.007) and tumor diameter (P = 0.052). Multivariate Cox regression analysis revealed that high CUL1 expression was an independent unfavorable prognostic factor for CRC patients (HR = 13.9, 95 % confidence interval = 5.89–32.6, P < 0.001). Moreover, we found that CUL1 over-expression induced CRC cell proliferation and the growth of xenografts in nude mice via the changing of cell-cycle proteins. In addition, increased CUL1 expression in CRC cells significantly promoted cell migration and invasion abilities in vitro and peritoneal metastasis in vivo through inducing high expression of MMPs.
Conclusion
Our findings imply that CUL1 may serve as promising prognostic markers in CRC patients.
Similar content being viewed by others
References
Bai J, Zhang J, Wu J, Shen L, Zeng J, Ding J, Wu Y, Gong Z, Li A, Xu S, Zhou J, Li G (2010) JWA regulates melanoma metastasis by integrin alphaVbeta3 signaling. Oncogene 29:1227–1237. doi:10.1038/onc.2009.408
Bai J, Zhou Y, Chen G, Zeng J, Ding J, Tan Y, Zhou J, Li G (2011) Overexpression of Cullin1 is associated with poor prognosis of patients with gastric cancer. Hum Pathol 42:375–383. doi:10.1016/j.humpath.2010.09.003
Bai J, Yong HM, Chen FF, Mei PJ, Liu H, Li C, Pan ZQ, Wu YP, Zheng JN (2013) Cullin1 is a novel marker of poor prognosis and a potential therapeutic target in human breast cancer. Ann Oncol 24:2016–2022. doi:10.1093/annonc/mdt147
Chaudhary AK, Pandya S, Ghosh K, Nadkarni A (2013) Matrix metalloproteinase and its drug targets therapy in solid and hematological malignancies: an overview. Mutat Res 753:7–23. doi:10.1016/j.mrrev.2013.01.002
Chen G, Li G (2010) Increased Cul1 expression promotes melanoma cell proliferation through regulating p27 expression. Int J Oncol 37:1339–1344
Chen G, Cheng Y, Martinka M, Li G (2010) Cul1 expression is increased in early stages of human melanoma. Pigment Cell Melanoma Res 23:572–574. doi:10.1111/j.1755-148X.2010.00725.x
Denicourt C, Dowdy SF (2004) Cip/Kip proteins: more than just CDKs inhibitors. Genes Dev 18:851–855. doi:10.1101/gad.1205304
Guardavaccaro D, Pagano M (2006) Stabilizers and destabilizers controlling cell cycle oscillators. Mol Cell 22:1–4. doi:10.1016/j.molcel.2006.03.017
Gupta GP, Massague J (2006) Cancer metastasis: building a framework. Cell 127:679–695. doi:10.1016/j.cell.2006.11.001
Hynes RO (2003) Metastatic potential: generic predisposition of the primary tumor or rare, metastatic variants-or both? Cell 113:821–823
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90. doi:10.3322/caac.20107
Libra M, Scalisi A, Vella N, Clementi S, Sorio R, Stivala F, Spandidos DA, Mazzarino C (2009) Uterine cervical carcinoma: role of matrix metalloproteinases (review). Int J Oncol 34:897–903
Mocciaro A, Rape M (2012) Emerging regulatory mechanisms in ubiquitin-dependent cell cycle control. J Cell Sci 125:255–263. doi:10.1242/jcs.091199
Nakayama KI, Nakayama K (2006) Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 6:369–381. doi:10.1038/nrc1881
Nguyen DX, Massague J (2007) Genetic determinants of cancer metastasis. Nat Rev Genet 8:341–352. doi:10.1038/nrg2101
Salon C, Brambilla E, Brambilla C, Lantuejoul S, Gazzeri S, Eymin B (2007) Altered pattern of Cul-1 protein expression and neddylation in human lung tumours: relationships with CAND1 and cyclin E protein levels. J Pathol 213:303–310. doi:10.1002/path.2223
Schmoll HJ, Stein A (2014) Colorectal cancer in 2013: towards improved drugs, combinations and patient selection. Nat Rev Clin Oncol. doi:10.1038/nrclinonc.2013.254
Sun Y, Shen S, Liu X, Tang H, Wang Z, Yu Z, Li X, Wu M (2014) miR-429 inhibits cells growth and invasion and regulates EMT-related marker genes by targeting Onecut2 in colorectal carcinoma. Mol Cell Biochem. doi:10.1007/s11010-013-1950-x
von Wasielewski R, Mengel M, Wiese B, Rudiger T, Muller-Hermelink HK, Kreipe H (2002) Tissue array technology for testing interlaboratory and interobserver reproducibility of immunohistochemical estrogen receptor analysis in a large multicenter trial. Am J Clin Pathol 118:675–682. doi:10.1309/URLK-6AVK-331U-0V5P
Wang S, Wu X, Zhang J, Chen Y, Xu J, Xia X, He S, Qiang F, Li A, Shu Y, Roe OD, Li G, Zhou JW (2013) CHIP functions as a novel suppressor of tumour angiogenesis with prognostic significance in human gastric cancer. Gut 62:496–508. doi:10.1136/gutjnl-2011-301522
Xie CM, Wei W, Sun Y (2013) Role of SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligases in skin cancer. J Genet Genomics 40:97–106. doi:10.1016/j.jgg.2013.02.001
Zheng N, Schulman BA, Song L, Miller JJ, Jeffrey PD, Wang P, Chu C, Koepp DM, Elledge SJ, Pagano M, Conaway RC, Conaway JW, Harper JW, Pavletich NP (2002) Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature 416:703–709. doi:10.1038/416703a
Acknowledgments
Research was supported by malignant tumor biomarkers in Jiangsu Province Key Laboratory (#11ZLKF09).
Conflict of interest
We declare that we have no conflict of interest.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Weimin Wang and Yansu Chen have contributed equally to this work.
Electronic supplementary material
Below is the link to the electronic supplementary material.
432_2015_1931_MOESM2_ESM.tif
Supplementary material 2 Fig. S1: Representative images of CUL1 immunohistochemical staining in human CRC. A, weak positive staining; B, moderate positive staining; C, strong positive staining; (A–C, original magnification, ×200) (TIFF 3509 kb)
432_2015_1931_MOESM3_ESM.tif
Supplementary material 3 Fig. S2: Receiver operating characteristic (ROC) curve is obtained to determine the optimal cutoff value of CUL1 expression. ROC obtains the area under the curves (AUC) at different cutoff values of CUL1 immunoreactivity score (IRS) for 1, 3 and 5 years of overall survival time (TIFF 847 kb)
432_2015_1931_MOESM4_ESM.tif
Supplementary material 4 Fig. S3: CUL1 positively regulated the SW480 cells migration and invasion in vitro. CUL1 over-expression in SW480 cells promoted cell migration and invasion, whereas CUL1 knockdown inhibited cell migration and invasion (A). Numbers of cell migration and invasion per field were counted in five random fields for CUL1 over-expressing/knockdown and control groups (n=3/group) in SW480 cells (B-C). Data were presented as means ± SD, *P < 0.05, **P < 0.001; Student’s t test (TIFF 3728 kb)
Rights and permissions
About this article
Cite this article
Wang, W., Chen, Y., Deng, J. et al. Cullin1 is a novel prognostic marker and regulates the cell proliferation and metastasis in colorectal cancer. J Cancer Res Clin Oncol 141, 1603–1612 (2015). https://doi.org/10.1007/s00432-015-1931-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-015-1931-4